These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8683863)

  • 1. [Interleukin-3 therapy in patients with aplastic anemia refractory to prior therapies].
    Miyairi Y; Murai K; Utsugisawa T; Narigasawa Y; Ito S; Shimosegawa K; Sugawara T; Numaoka H; Ono Y; Ito T; Ishida Y; Kuriya S
    Rinsho Ketsueki; 1996 Jan; 37(1):22-8. PubMed ID: 8683863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia.
    Bessho M; Jinnai I; Hirashima K; Saito M; Murohashi I; Ino H; Tsuji M; Fukuda M; Maruyama M; Kusumoto S
    Stem Cells; 1994 Nov; 12(6):604-15. PubMed ID: 7533579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia.
    Raghavachar A; Ganser A; Freund M; Heimpel H; Herrmann F; Schrezenmeier H
    Cytokines Mol Ther; 1996 Dec; 2(4):215-23. PubMed ID: 9384707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Two patients with aplastic anemia successfully treated with G-CSF and erythropoietin].
    Hanamura A; Ichikawa A; Utsumi M; Hotta T
    Rinsho Ketsueki; 1995 Dec; 36(12):1347-52. PubMed ID: 8587170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sustained long-term complete remission in an elderly aplastic anemia patient after cessation of combined therapy consisting of granulocyte-colony stimulating factor and erythropoietin].
    Yasuyama M; Kawauchi K; Sugiyama H; Ohkawa S
    Rinsho Ketsueki; 2000 Jan; 41(1):42-7. PubMed ID: 10695398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A phase III trial of subcutaneous administration of rhG-CSF in aplastic anemia].
    Yoshida Y; Okuma M; Suzuki T; Takahashi T; Nakagawa M; Kashima K; Abe T; Sonoda Y; Fujii H; Haruyama H
    Rinsho Ketsueki; 1994 Nov; 35(11):1282-8. PubMed ID: 7529841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia.
    Takahashi M; Aoki A; Mito M; Nikkuni K; Ohtsuka T; Saitoh H; Moriyama Y; Shibata A
    Hematol Pathol; 1993; 7(3):153-8. PubMed ID: 8244908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aplastic anemia successfully treated with erythropoietin and rhG-CSF].
    Higashino K; Kito K; Hodohara K; Fujiyama Y; Banba T; Hosoda S
    Rinsho Ketsueki; 1992 Sep; 33(9):1237-41. PubMed ID: 1279235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [RAEB in T with monosomy 7 after treatment of severe aplastic anemia with long term G-CSF].
    Kaito K; Otsubo H; Ogasawara Y; Sekita T; Saeki A; Nishiwaki K; Masuoka H; Shimada T; Kobayashi M; Sakai O
    Rinsho Ketsueki; 1995 Apr; 36(4):365-70. PubMed ID: 7540227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer.
    Perillo A; Pierelli L; Battaglia A; Salerno MG; Rutella S; Cortesi E; Fattorossi A; De Rosa L; Ferraù F; Lalle M; Leone G; Mancuso S; Scambia G
    Bone Marrow Transplant; 2002 Nov; 30(9):571-8. PubMed ID: 12407431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3-line response following long-term therapy of severe aplastic anemia using glycosylated rHuG-CSF: dysfunctional thrombocytes as early indication of a myelodysplastic syndrome].
    Caspar CB; von Felten A; Widmer L; Burger J; Gmür J
    Schweiz Med Wochenschr; 1994 Jan; 124(1-2):69-72. PubMed ID: 7507600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of hematopoietic progenitor cells in patients with severe aplastic anemia who obtained good clinical response with a combination therapy of immunosuppressive agents and recombinant human granulocyte colony-stimulating factor.
    Matsuo Y; Iwanaga M; Mori H; Yoshida S; Kawaguchi Y; Yakata Y; Murata K; Nagai K; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M
    Int J Hematol; 2000 Jul; 72(1):37-43. PubMed ID: 10979207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients.
    Kolbe K; Peschel C; Rupilius B; Després D; Burger K; Sklenar I; Färber L; Huber C; Derigs HG
    Bone Marrow Transplant; 1997 Dec; 20(12):1027-32. PubMed ID: 9466274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.